The vaccine was intended to be ready for use after clinical trials in November or December, however, because swine influenza still was considered to be a mild disease, the influenza vaccine could not be used without approval by the European Medicines Agency (EMEA).
The vaccine was intended to be ready for use after clinical trials in November or December because swine influenza still was considered to be a mild disease, the influenza vaccine could not be used without approval by the European Medicines Agency (EMEA). This was however.